 IRVINE, Calif., Sept. 28, 2021 GLOBE NEWSWIRE -- Reneo Pharmaceuticals, Inc. NASDAQ: RPHM, a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will host a key opinion leader KOL webinar on McArdle Disease and other genetic mitochondrial myopathies on Monday, October 4, 2021, at 12 pm Eastern Time. 